Introduction: Recent studies have suggested that segmentectomy may be an acceptable alternative treatment to lobectomy for surgical management of smaller lung adenocarcinomas. The objective of this study was to compare survival after lobectomy and segmentectomy among patients with pathological stage IA adenocarcinoma categorized as stage T1b (>0 to 20 mm) according to the new eighth edition of the TNM system.
Methods:
In total, 7989 patients were identified from the Surveillance, Epidemiology, and End Results registry. Propensity scores generated from logistic regression on preoperative characteristics were used to balance the selection bias of undergoing segmentectomy. Overall and lung cancer-specific survival rates of patients undergoing segmentectomy and lobectomy were compared in propensity score-matched groups.
Results: Overall, 564 patients (7.1%) underwent segmentectomy. Lobectomy led to better overall and lung cancerspecific survival than segmentectomy for the entire cohort (log-rank p < 0.01). After 1:2 propensity score matching, segmentectomy (n ¼ 552) was no longer associated with significantly worse overall survival (5-year survival ¼ 74.45% versus 76.67%, hazard ratio ¼ 1.09, 95% confidence interval: 0.90-1.33) or lung cancer-specific survival (5-year survival ¼ 83.89% versus 86.11%, hazard ratio ¼ 1.12, 95% confidence interval: 0.86-1.46) compared with lobectomy (n ¼ 1085) after adjustment for age, sex, lymph node quantity, and histological subtype. Similar negative findings were identified when patients were stratified according to sex, age, histological subtype, and number of evaluated lymph nodes.
Conclusions:
Patients who underwent segmentectomy may have survival outcomes no different than those of some patients who received lobectomy for pathological stage IA adenocarcinomas at least 10 but no larger than 20 mm in size. These results should be further confirmed through prospective randomized trials.
outcomes similar to those of lobectomy in early-stage NSCLC that measure 2 cm or less. 1 Data from the latest NSCLC staging project found that the prognosis differs for tumors sized from 1 to 5 cm, which subsequently led to the reclassification of T descriptors in the revised system. 2 Of particular interest, tumors that were previously defined as T1a (2 cm) will be subclassified as T1a (1 cm) and T1b (>1 to 2 cm). In this study, we used the population-based Surveillance, Epidemiology, and End Results (SEER) registry to test the hypothesis that the survival of patients with new pathological T1bN0M0 lung adenocarcinomas who undergo segmentectomy will not be inferior to that of patients undergoing lobectomy.
Methods

Study Population
The population was selected from the SEER 18 registry and limited to patients in whom stage IA lung adenocarcinomas that measured at least 10 but no more than 20 mm were histologically diagnosed and treated with segmentectomy or lobectomy from 2004 to 2012.
Patients' sociodemographic information and tumor characteristics were collected. Tumor histological subtype was coded according to the 2004 WHO classification. 3 Survival was defined as the interval from diagnosis until death or last follow-up. Patients who survived past 31 December 2013 were classified as censored cases. When lung cancer-specific survival (LCSS) was analyzed, causes of death other than lung cancer were treated as censored observations. The completeness of follow-up was measured by a modification of Clark's method. 4 The local institutional review board classified this study as exempt.
Statistical Analysis
Overall survival (OS) and LCSS were the primary and secondary outcomes of interest. The Kaplan-Meier method was used to compare unadjusted survival of patients undergoing segmentectomy or lobectomy with a log-rank test. Propensity score matching was used to balance the potential probability of being assigned to a treatment group. A logistic regression model that included age, sex, ethnicity, marital status, tumor laterality, location, and size was used to calculate the propensity scores, and 1: 2 pair matching without replacement was implemented by greedy nearest neighbour matching. 5 The covariable balance effect was assessed by a standardized difference with a threshold of 0.10. Multivariable Cox proportional hazards models that included variables with a p value less than 0.2 on univariable analysis were used to decide variables that remained in the final model. A Cox proportional hazards model adjusted for age, sex, histological subtype, and number of lymph nodes evaluated was applied to compare outcomes between groups.
We also performed secondary subgroup analysis limited to patients with different sex, age (<70 versus 70 years), histological subtype (nonmucinous bronchioloalveolar carcinoma, mucinous adenocarcinoma, and remaining adenocarcinoma subtypes [major adenocarcinoma]), and number of lymph nodes examined (0-10 versus >10). 6 The study aim was to test whether segmentectomy was not inferior to lobectomy in treating certain stage IA lung adenocarcinomas. Noninferiority was established at the level of significance if the onesided upper 95% confidence bound was below the prespecified margin of 1.25. 7 Statistical power was calculated accordingly. 8 Analyses were conducted by using PASW Statistics 18 statistical software (formerly SPSS Statistics [SPSS, Hong Kong Special Administrative Region, People's Republic of China]).
Results
A flow diagram is presented in Figure 1 . In total, 7989 patients were identified, of whom 564 (7.1%) underwent segmentectomy. The baseline characteristics are reported in Table 1 . Segmentectomy was performed more often in cases involving seniors, left-side tumors, lower lobes, and smaller lesions. After propensity score matching, 552 segmentectomies and 1085 lobectomies were preserved. Preoperative characteristics were well balanced (Fig. 2) . However, those in the segmentectomy arm were more likely to have lower lobe cancer, nonmucinous bronchioloalveolar carcinoma (p [ 0.02), and fewer lymph nodes resected (p < 0.01) regardless of matching. A higher incidence of more than 10 lymph nodes resected was observed in the lobectomy group (259 of 1085 [23.9%] versus 56 of 552 [10.1%] ).
The median follow-up interval was 52.21 months (0-119 months) before matching. Patients who underwent segmentectomy had worse unadjusted OS and LCSS (both p < 0.01 [ Supplementary Fig. 1]) . More than 10 lymph nodes resected was associated with better OS (p ¼ 0.03) and LCSS (p < 0.01) (Supplementary Fig. 2 ). After propensity score matching, the median follow-up intervals were 49.24 months (0-119 months) and 52.06 months (0-119 months) for segmentectomy and lobectomy, respectively. The follow-up modified Clark's C statistic values were 91.52% and 81.46% for OS and LCSS, respectively.
The unadjusted Cox proportional hazard model showed that segmentectomy provided outcomes no different from those of lobectomy in terms of OS (5- Supplementary Fig. 1 ). Age, sex, lymph node quantity, and histological subtype (not for LCSS) were identified as potential predictors for survival function under multivariable analyses (Supplementary Table 1 ). The regression model adjusting for these factors showed that segmentectomy was consistently associated with outcomes that were no different in terms of OS (5-year survival ¼ 74.45% versus 76.67%, HR ¼ 1.09, 95% CI: 0.90-1.33) and LCSS (5-year survival ¼ 83.89% versus 86.11%, HR ¼ 1.12, 95% CI ¼ 0.86-1.46) from those of lobectomy (Fig. 3) . On secondary analysis, we did not recognize different OS or LCSS rates when patients were divided according to the number of lymph nodes or pathological subtypes. Demographic characteristics in the subsets of major adenocarcinomas and those with 10 or fewer resected lymph nodes are shown in Supplementary Table 2. Consistent negative results were found when patients were stratified by age, sex, or size (Fig. 4) . However, all statistical powers were less than 0.8 for these analyses.
Discussion
In the current study of pathological stage IA lung adenocarcinomas larger than 10 and but no larger than 20 mm, we evaluated the survival outcomes of segmentectomy versus those of lobectomy in a noninferiority setting. Our findings showed that segmentectomy has survival no different than that of lobectomy for this specified population.
Tailored therapy for patients with early-stage NSCLCs is still an issue of debate. 9 A recent report has demonstrated that sublobar resection may achieve outcomes similar to those of lobectomy for NSCLCs 
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Segmentectomy in Stage IA Adenocarcinomas1 cm or smaller. 10 However, limited resection was not equivalent to lobectomy in older patients with lesions 2 cm or smaller. 11 Besides tumor size, histological subtype may be another important factor that affects the outcome of sublobar resection. Whether the real therapeutic effect of segmentectomy was underestimated by including patients who underwent wedge resection 12 or were classified as having squamous carcinoma 11 or overestimated by including lesions smaller than 1 cm remains unclear. 10 Thus, we restricted the study population to those who had a pathological stage IA lung adenocarcinoma at least 1 but no larger than 2 cm in size and underwent segmentectomy and lobectomy only.
More than 10 examined lymph nodes was a strong predictor of survival for node-negative early-stage NSCLC 6 ; hence, we integrated this parameter as well as other prognostic confounders into the Cox models for better adjustment. Although lobectomy was associated with higher chance of more than 10 resected lymph nodes, we did not observe a survival difference for segmentectomy versus lobectomy in subgroups divided by number of lymph nodes. However, an intentional segmentectomy with a minimum of 10 lymph nodes resected should be explored in a prospective trial.
Histological subtype of lung adenocarcinoma has recently been proved to be a crucial factor that affects the survival of patients who undergo sublobar resection. One pilot study found that lobectomy did not offer an OS advantage over sublobar resection for invasive adenocarcinomas 2 cm or smaller according to the 2011 adenocarcinoma classification, 13 although the number of limited resections was quite small (n ¼ 26). 1 However, another population-based study found that limited resection was inferior to lobectomy in invasive lung adenocarcinomas 2 cm or smaller, whereas segmentectomy seemed to be equivalent to lobectomy on a subgroup analysis. 11 On the basis of the results of our study, we postulate that the discrepancy could be attributed to the high proportion of patients with wedge resections (nearly 80%) who underwent sublobar resection in the latter study, which would potentially override the therapeutic benefit of segmentectomy.
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This study had certain limitations. Preoperative cardiopulmonary function is not available in the SEER registry, which makes it difficult to balance the higher likelihood of choosing patients with poorer cardiopulmonary status to receive sublobar resection. The lack of exact tumor location made it hard to estimate whether the lesion was amenable to segmentectomy. In addition, we were unable to evaluate whether segmentectomy would lead to better preservation of lung function, a greater chance of receiving adjuvant chemotherapy, a higher rate of insufficient margins, or relapse. Additionally, the new classification of adenocarcinoma has not been updated in the SEER registry 13 ; therefore, the study population in this study was still heterogeneous. Patients with even small proportions of micropapillary or solid components have a worse prognosis, which may affect the decision to perform a sublobar procedure. 14, 15 Furthermore, the lack of clinical staging forced us to select patients solely on the basis of pathological stage, which would inevitably exclude some clinical stage IA cases that were found to be pathological stage IB (e.g., pleural invasion). As excluding such patients would falsely improve survival, the ability to apply the current findings to all clinical stage IA patients could be limited.
